Obesity Paradox and Lung Cancer, Metformin-based Therapeutic Opportunity? | Oncotarget

Posted by

Oncotarget

Oncotarget published this trending editorial on July 1, 2023 in Volume 14, entitled, “Obesity paradox and lung cancer, metformin-based therapeutic opportunity?" by researchers from the Thoracic Oncology Functional Unit (UFOT), Laboratorio de Medicina Personalizada, Instituto Nacional de Cancerología, S.S.A., Mexico City. DOI - https://doi.org/10.18632/oncotarget.28432 Correspondence to - Oscar Arrieta - ogarrieta@gmail.com Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28432 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, obesity, lung cancer, metformin, tyrosine-kinase inhibitors, BMI, EGFR, obesity paradox About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957